iSpecimen Inc. (ISPC) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ISPC scores 30 out of 100 with a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The fundamental cash engine pillar scores 9 of 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on invested capital or free cash flow. The whale 13F flow pillar scores 3 of 20 and the insider conviction pillar scores 3 of 20, reflecting weak institutional and insider signal support. The macro regime fit pillar scores 7 of 20 (Beta 1.0; sector sensitivity). The forensic balance sheet pillar scores 8 of 20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). For a prospective investor evaluating the stock today, the rating points to a business with negative returns, no free cash yield, weak ownership signals, and a forensic profile that the rating treats as elevated risk. Any upside case would need to rest on a change in those fundamentals, which the source data does not show.

iSpecimen Inc. (ISPC) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Commercial Physical & Biological Resarch industry. The source data does not describe its specific products, customers, or revenue model beyond its reported revenue figures. Gross margin is reported at 11.2% per the market data section.

Per the SEC financials, revenue declined from $9.9M in FY 2023 and $9.3M in FY 2024 to $1.9M in FY 2025, while net income was negative in every reported period. Operating margin is reported at -60% and net margin at -60% per the market data section. ROIC is reported at -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, both per the Roarable RQD rating, and Debt/Equity is 0.5 per the same source; the source does not provide the underlying debt figures.

Per the recent news wire, the most prominent item is a report that a 1-for-10 to 1-for-100 reverse split goes to iSpecimen (ISPC) voters October 30, flagged as a market wire item. A Stock Titan item covering shipping of healthy donor blood the day it is collected is flagged green as a catalyst, though the source does not link it to a specific ISPC business event. Two items flagged red as risk watch report the stock falling -0.76% and watching $0.86 support as of 2026-10-20. A Benzinga item lists ISPC among 12 Health Care stocks moving in after-market trading. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

• What is the outcome of the reverse split vote scheduled for October 30, and what share-count change would result?
• What products or services generate the reported revenue, and why did revenue decline from $9.9M in FY 2023 to $1.9M in FY 2025?
• What are the debt, EPS, and forward earnings figures underlying the reported Debt/Equity and valuation gaps?
• What is the cash runway given $6.9M cash against FY 2025 free cash flow of $-4.2M?
• Do the reported news items link to any specific business event, or are they market-monitoring summaries?